Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4H-chromene-3-carboxylate (sHA 14-1) and its analogues

Journal of Medicinal Chemistry

Volumn 52, Issue 19, 2009, Pages 5937-5949

  Das, Sonia G ^a   Doshi, Jignesh M ^a   Tian, Defeng ^a   Addo, Sadiya N ^a   Srinivasan, Balasubramanian ^a   Hermanson, David L ^a   Xing, Chengguo ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; CAMPTOTHECIN; CASPASE 3; CASPASE 7; ETHYL 2 AMINO 4 (2 ETHOXY 2 OXOETHYL) 6 PHENYL 4H CHROMENE 3 CARBOXYLATE (SHA 14 1); MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CYTOTOXICITY; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

APOPTOSIS; BENZOPYRANS; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; MITOXANTRONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349638919     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9005059     Document Type: Article

References (35)

1. Bernards, R. Finding biomarkers of resistance to targeted cancer therapies. EJC Suppl. 2007, 5, 109-114.
2. Wang, J. L.; Liu, D.; Zhang, Z. J.; Shan, S.; Han, X.; Srinivasula, S. M.; Croce, C. M.; Alnemri, E. S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A 2000, 97, 7124-7129.
3. Lage, H. An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 2008, 65, 3145-3167.
4. Mimeault, M.; Hauke, R.; Batra, S. K. Recent Advances on the Molecular Mechanisms Involved in the Drug Resistance of Cancer Cells and Novel Targeting Therapies. Clin. Pharmacol. Ther. 2007, 83, 673-691.
5. Monti, E. Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors. In Cancer Drug Resistance, Teicher, B. A., Ed.; Humana Press: Totowa, NJ, 2006; pp 241-260.
6. Mellor, H. R.; Callaghan, R. Resistance to Chemotherapy in Cancer:A Complex and Integrated Cellular Response. Pharmacology 2008, 81, 275-300. (Pubitemid 351666917)
7. Elmore, S. Apoptosis: A Review of Programmed Cell Death. Toxicol. Pathol. 2007, 35, 495-516.
8. Adams, J. M. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003, 17, 2481-2495.
9. Degterev, A.; Yuan, J. Expansion and evolution of cell death programmes. Nat. Rev. Mol. Cell Biol. 2008, 9, 378-390.
10. Reed, J. C.; Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood 2005, 106, 408-418.
11. Su, Y.; Zhang, X.; Sinko, P. J. Exploitation of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: a promising new approach to the treatment of multidrug resistant cancer. Cancer Lett. 2007, 253, 115-123.
12. Cory, S.; Huang, D. C.; Adams, J. M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22, 8590-8607. (Pubitemid 38028528)
13. Reed, J. C.; Zha, H.; Aime-Sempe, C.; Takayama, S.; Wang, H. G. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv. Exp. Med. Biol. 1996, 406, 99-112.
14. Krajewski, S.; Tanaka, S.; Takayama, S.; Schibler, M. J.; Fenton, W.; Reed, J. C. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 1993, 53, 4701-4714.
15. Rong, Y.; Distelhorst, C. W. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu. Rev. Physiol. 2008, 70, 73-91.
16. Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59.
17. Kang, M. H.; Reynolds, C. P. Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy. Clin. Cancer Res. 2009, 15, 1126-1132.
18. Hao, J.-H.; Yu, M.; Liu, F.-T.; Newland, A. C.; Jia, L. Bcl-2 Inhibitors Sensitize Tumor Necrosis Factor-Related Apoptosis- Inducing Ligand-Induced Apoptosis by Uncoupling of Mitochondrial Respiration in Human Leukemic CEM Cells. Cancer Res. 2004, 64, 3607-3616. (Pubitemid 38657939)
19. Manero, F.; Gautier, F.; Gallenne, T.; Cauquil, N.; Gree, D.; Cartron, P.-F.; Geneste, O.; Gree, R.; Vallette, F. M.; Juin, P. The Small Organic Compound HA14-1 Prevents Bcl-2 Interaction with Bax to Sensitize Malignant Glioma Cells to Induction of Cell Death. Cancer Res. 2006, 66, 2757-2764.
20. Pei, X. Y.; Dai, Y.; Grant, S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA 14-1 in multiple myeloma cells. Leukemia 2003, 17, 2036-2045. (Pubitemid 37322135)
21. Doshi, J. M.; Tian, D.; Xing, C. Ethyl-2-amino-6-bromo-4-(1- cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14- 1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis. Mol. Pharm. 2007, 4, 919-928.
22. Tian, D.; Das, S. G.; Doshi, J. M.; Peng, J.; Lin, J.; Xing, C. sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett. 2008, 259, 198-208.
23. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681.
24. Harker, W. G.; Slade, D. L.; Dalton, W. S.; Meltzer, P. S.; Trent, J. M. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 1989, 49, 4542-4549.
25. Harker, W. G.; Slade, D. L.; Drake, F. H.; Parr, R. L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 1991, 30, 9953-9961.
26. Fujimori, A.; Harker, W. G.; Kohlhagen, G.; Hoki, Y.; Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 1995, 55, 1339-1346.
27. Kapoor, R.; Slade, D. L.; Fujimori, A.; Pommier, Y.; Harker, W. G. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 1995, 7, 83-95.
28. Apostolidou, E.; Swords, R.; Alvarado, Y.; Giles, F. J. Treatment of Acute Lymphoblastic Leukemia: A New Era. Drugs 2007, 67, 2153-2171. (Pubitemid 47557092)
29. Ravandi, F.; Burnett, A. K.; Agura, E. D.; Kantarjian, H. M. Progress in the treatment of acute myeloid leukemia. Cancer 2007, 110, 1900-1910. (Pubitemid 350041630)
30. Kuendgen, A.; Germing, U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat. Rev. 2009, 35, 97-120.
31. Pui, C.-H.; Jeha, S. New therapeutic strategies for the treatment of acute lymphoblastic leukemia. Nat. Rev. Drug Discovery 2007, 6, 149-165.
32. Reed, J. C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008, 111, 3322-3330.
33. Doshi, J. M.; Tian, D.; Xing, C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)- 4H-chromene-3- carboxylate (HA14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J. Med. Chem. 2006, 49, 7731-7739.
34. Hurwitz, R.; Hozier, J.; LeBien, T.; Minowada, J.; Gajl-Peczalska, K.; Kubonishi, I. Kersey, J. Characterization of a leukemic cell line of the pre-B phenotype. Int. J. Cancer 1979, 23, 174-180. (Pubitemid 9110051)
35. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.